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Introduction
Besides the fertility disturbance, patients with hypo-
gonadism have an increased risk of cardiometabolic 
diseases such as type 2 diabetes, hypertension, dyslipi-
daemia, or obesity [1–4]. This increased cardiometabolic 
risk is present even in young ages in patients with 
congenital hypogonadotropic hypogonadism (CHH) 
[1]. Although the exact mechanism of increased cardio-
metabolic disease risk is not fully elucidated, endothe-
lial dysfunction, inflammation, and insulin resistance 
have been reported as the main pathophysiological 
pathways of this increased risk in patients with hypo-
gonadism [3, 5, 6]. 
The triglyceride-glucose (TyG) index, which is cal-
culated using fasting glucose and triglyceride levels, 
has recently been reported as a novel surrogate marker 
of insulin resistance [7–9]. The TyG index has been re-
ported to show good correlation with hyperinsulinae-
mic euglycaemic clamp test and homeostasis model 
assessment for insulin resistance (HOMA-IR) [8, 10]. 
Recent studies also reported that increased TyG index 
levels are strongly associated with cardiometabolic 
diseases such as type 2 diabetes [11], hypertension [12], 
nonalcoholic fatty liver disease [13], and cardiovascular 
diseases [14].
The TyG index may also be associated with in-
creased cardiometabolic risk in hypogonadism pa-
tients. However, there are very limited data about the 
TyG index levels in patients with hypogonadism. Also, 
there are no data about the relationship between TyG 
levels and endothelial dysfunction and insulin resis-
tance in patients with CHH. Therefore, we designed 
this study to search for the answers to the following 
questions: 1 — Is there any difference between patients 
with CHH and healthy controls in terms of TyG index 
levels? 2 — Is there any association between TyG index 
and surrogate markers of endothelial dysfunction, in-
sulin resistance, and inflammation in treatment-naïve 
patients with CHH? 
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Abstract 
Introduction: The risk of cardiometabolic diseases is increased in patients with hypogonadism. The triglyceride-glucose (TyG) index is 
a novel surrogate marker of insulin resistance and is associated with cardiovascular diseases. We investigated the TyG index levels and 
the relationship with endothelial dysfunction and insulin resistance in patients with congenital hypogonadotropic hypogonadism (CHH).
Material and methods: A total of 98 patients with CHH (mean age 21.66 ± 1.99 years) and 98 healthy control subjects (mean age 21.69 ± 
1.21 years) were enrolled. The demographic parameters, TyG index, asymmetric dimethylarginine (ADMA), high-sensitivity C-reactive 
protein (hs-CRP), and homeostatic model assessment of insulin resistance (HOMA-IR) levels were measured for all participants.
Results: The patients had higher waist circumference (p < 0.001), triglycerides (p = 0.001), insulin (p = 0.003), HOMA-IR (p = 0.002), 
ADMA (p < 0.001), and TyG index (p < 0.001) levels and lower HDL-C (p = 0.044) and total testosterone (p < 0.001) levels compared to 
healthy control subjects. TyG index levels significantly correlated with the ADMA (r = 0.31, p = 0.003) and HOMA-IR (r = 0.32, p < 0.001) 
levels. TyG index was also determinant of HOMA-IR levels (ß = 0.20, p = 0.018).
Conclusion: The results of the present study show that patients with CHH had increased TyG index levels. Also, the TyG index is inde-
pendently associated with insulin resistance in patients with CHH. Long-term follow-up studies are warranted to find out the role of the 
TyG index in determining cardiometabolic risk in patients with hypogonadism. (Endokrynol Pol 2021; 72 (3): 232–237)
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signed-rank test, as appropriate. Inter-group differences were ana-
lysed by Student’s t-test and Mann-Whitney U test as appropriate. 
Relationships between ADMA and HOMA-IR levels and clinical 
and biochemical parameters were evaluated by Pearson correlation 
coefficients. Differences were considered significant at p < 0.05.
Results
The demographic and biochemical characteristics of the 
patients and the control subjects are given in Table 1. 
A total of 98 patients with CHH and 98 healthy control 
subjects were included. The two groups were similar 
with regard to age and BMI. Waist circumference 
(p < 0.001), triglycerides (p = 0.001), insulin (p = 0.003), 
HOMA-IR (p = 0.002), ADMA (p < 0.001), and TyG 
index (p < 0.001) levels were significantly higher and 
HDL-C (p = 0.044) and total testosterone (p < 0.001) 
levels significantly lower in patients with CHH, com-
pared to healthy control subjects.
To define whether ADMA and HOMA-IR levels were 
associated with demographic and clinical parameters, 
basic biochemical results, or TyG index, we performed 
a Pearson correlation analysis. There were negative 
correlations between plasma ADMA levels and BMI 
(r = –0.24, p = 0.027), HDL-C (r = –0.25, p = 0.021), 
total testosterone (r = –0.70, p < 0.001), FSH (r = –0.49, 
p < 0.001), and LH (r = –0.59, p < 0.001) and positive 
correlations between plasma ADMA levels and total-C 
(r = 0.23, p = 0.041), triglycerides (r = 0.30, p = 0.004), 
LDL-C (r = 0.24, p = 0.028), and TyG index (r = 0.31, 
p = 0.003). HOMA-IR levels were correlated negatively 
with total testosterone (r = –0.25, p = 0.002), and they 
correlated positively with BMI (r = 0.27, p = 0.001), 
waist circumference (r = 0.41, p < 0.001), glucose 
(r = 0.28, p = 0.001), triglycerides (r = 0.23, p = 0.006), 
insulin (r = 0.99, p < 0.001), and Tyg index levels 
(r = 0.32, p < 0.001) (Tab. 2).
Multiple regression analysis was applied to test the 
independent link between ADMA and HOMA-IR levels 
and potential functional correlates of these outcome 
variables. The multivariate analysis has shown that 
total testosterone levels (b = –0.71, p = 0.001) were the 
only independent determinant of plasma ADMA levels, 
while waist circumference (b = 0.26, p = 0.045) and TyG 
index levels (b = 0.20, p = 0.018) were the determinants 
of the HOMA-IR levels (Tab. 3).
Discussion
The results of the present study show that patients with 
CHH have higher plasma ADMA, HOMA-IR, and TyG 
index levels than the healthy control subjects. Moreover, 
the TyG index is significantly correlated with plasma 
ADMA and HOMA-IR levels and is applicable as the 
independent predictor of HOMA-IR levels. These 
Material and methods
Study design and population
This cross-sectional study was performed by evaluating the hy-
pogonadism database of the department of Endocrinology and 
Metabolism of a tertiary centre. The study group consisted of male 
subjects with CHH (n = 98, mean age 21.66 ± 1.99 years), and 
age- and body mass index (BMI)-matched male healthy volunteers 
(n = 98, mean age 21.69 ± 1.21 years). Patients who were previously 
given testosterone or human chorionic gonadotropin (hCG) therapy 
and with any chronic diseases or organ dysfunction were excluded. 
None of the control subjects had a chronic disorder or used any 
medications, including over-the-counter drugs. All subjects gave 
informed consent, and the Local Ethical Committee of Gulhane 
School of Medicine approved the study. A portion of the data for 
this study population was previously published [1, 15]. 
Detailed medical histories of all patients and control subjects were 
obtained before the study. The height, weight, and waist circumfer-
ence of the patients and control subjects were measured with them 
wearing just their underwear. The BMI was computed as the ratio 
of weight to the square of height (kg/m2). Waist circumference was 
measured on the line between the iliac crest and the lower costal 
margin parallel to the ground after subjects exhaled. Pubertal de-
velopment of the patients was evaluated according to the Tanner 
stages. The diagnosis of CHH was based on a failure to undergo 
spontaneous puberty before 18 years of age and was confirmed by 
low serum total testosterone levels and normal or low gonadotropin 
levels. Pituitary hormones were evaluated in all patients to exclude 
panhypopituitarism. Pituitary or hypothalamic mass lesions were 
excluded by magnetic resonance imaging.
Sample collection and laboratory measurements
Venous blood samples were drawn from patients and control 
subjects between 08:00 and 09:00 h after overnight fasting for bio-
chemical analyses. The samples were centrifuged for 15 min at 4000 
g, aliquoted, and immediately frozen at −80°C for analyses. Fasting 
plasma glucose, total cholesterol, triglyceride, and high-density lipo-
protein cholesterol (HDL-C) levels were measured by the enzymatic 
colorimetric method with an Olympus AU2700 auto analyser using 
reagents from Olympus Diagnostics (GmbH, Hamburg, Germany). 
Low-density lipoprotein cholesterol (LDL-C) was calculated by 
Friedewald’s formula [16]. The serum basal insulin level, total 
testosterone, follicle stimulating hormone (FSH), and luteinizing 
hormone (LH) were measured by the chemiluminescence method 
with a Unice lDXI 800 Access Immunoassay System (Miami, FL, ABD). 
Insulin sensitivity was calculated by using the homeostatic model 
assessment-insulin resistance (HOMA-IR) by the following formula:
HOMA-IR = (insulin × glucose)/405.
TyG index is the logarithm (Ln) of (fasting blood glucose (mg/ dL) 
× TG(mg/dL)/2) [10]. Plasma asymmetric dimethylarginine (ADMA) 
levels were measured by ELISA (Immundiagnostik, Bensheim, Ger-
many). The minimum detectable concentration for ADMA was 0.05 
μmol/L. High-sensitivity C-reactive protein (hs-CRP) levels were 
determined in serum by immunoturbidimetric fixed rate method 
using an Olympus AU-2700 autoanalyzer (Hamburg, Germany). 
Intraassay coefficient of variation (CV) and interassay CV were 5.8% 
and 3.1%, respectively. The minimum detectable concentration for 
hs-CRP was 0.07 mg/L.
Statistical analyses
All data were recorded on a computer database and analysed using 
SPSS 15.0 package program (SPSS, Inc., Chicago, IL, USA). Results 
were expressed as mean ± S.D. The variables were assessed for 
normality using Kolmogorov-Smirnov test, and Levene’s test was 
used to evaluate the equality of variance. Intragroup changes at 
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findings imply that the TyG index may be a useful and 
practical measure for assessing insulin resistance in pa-
tients with CHH. To our knowledge, the current study 
is the first to show the levels of the TyG index and its 
relationship with endothelial dysfunction and insulin 
resistance in patients with CHH.
Table 1. Demographic and metabolic parameters of patients with congenital hypogonadotropic hypogonadism (CHH) 
and healthy controls 
Healthy controls 
 [n = 98]
Patients with CHH 
 [n = 98] p
Age [year] 21.69 ± 1.21 21.66 ± 1.99 0.897
BMI [kg/m2] 23.00 ± 2.21 22.28 ± 3.40 0.082
WC [cm] 79.58 ± 6.50 84.80 ± 10.95 < 0.001
FBG [mg/dL] 83.89 ± 10.36 85.94 ± 7.27 0.110
Total-C [mg/dL] 153.20 ± 34.66 161.18 ± 26.88 0.083
TG [mg/dL] 81.03 ± 33.56 105.58 ± 60.21 0.001
LDL [mg/dL] 86.32 ± 30.09 92.09 ± 22.31 0.138
HDL [mg/dL] 51.19 ± 15.34 47.44 ± 10.02 0.044
FSH [mIU/mL] 3.69 ± 2.47 1.34 ± 4.74 0.001
LH [mIU/mL] 5.06 ± 1.84 0.82 ± 3.26 <0.001
T. Testosterone [ng/mL] 540.32 ± 120.52 29.66 ± 27.97 <0.001
Insulin [µU/mL] 7.20 ± 4.77 9.97 ± 5.94 0.003
HOMA-IR 1.49 ± 1.10 2.12 ± 1.31 0.002
hs-CRP [mg/L] 0.92 ± 1.29 1.18 ± 1.10 0.241
ADMA [µmol/L] 0.34 ± 0.06 0.66 ± 0.16 < 0.001
TyG index 8.04 ± 0.48 8.30 ± 0.49 < 0.001
BMI — body mass index; WC — waist circumference; FBG — fasting blood glucose; Total C — total cholesterol; TG — triglyceride; LDL — low-density lipoprotein 
cholesterol; HDL — high-density lipoprotein cholesterol; FSH — follicle stimulating hormone; LH — luteinizing hormone; T. Testosterone — serum total testosterone; 
HOMA-IR — homeostatic model assessment of insulin resistance; hs-CRP — high-sensitivity C-reactive protein; ADMA — asymmetric dimethylarginine;  
TyG Index — triglyceride–glucose index
Table 2. Correlation analysis between asymmetric dimethylarginine (ADMA), homeostatic model assessment of insulin 
resistance (HOMA-IR), and clinical and biochemical parameters
ADMA HOMA-IR
r p r p
BMI [kg/m2] –0.235 0.027 0.267 0.001
WC [cm] 0.105 0.359 0.406 < 0.001
FBG [mg/dL] 0.101 0.349 0.278 0.001
Total-C. [mg/dL] 0.225 0.041 –0.023 0.785
Triglyceride [mg/dL] 0.299 0.004 0.225 0.006
HDL [mg/dL] –0.245 0.021 –0.150 0.070
LDL [mg/dL] 0.244 0.028 –0.024 0.778
Insulin [µU/mL] 0.217 0.059 0.987 < 0.001
TyG Index 0.309 0.003 0.321 < 0.001
hsCRP [mg/L] 0.153 0.162 0.154 0.115
T. Testosterone [ng/mL] –0.703 < 0.001 –0.253 0.002
FSH [mIU/mL] –0.486 < 0.001 0.066 0.478
LH [mIU/mL] –0.585 < 0.001 –0.030 0.744
BMI — body mass index; WC — waist circumference; FBG — fasting blood glucose; Total C. — total cholesterol; TG — triglyceride; LDL — low-density lipoprotein 
cholesterol; HDL — high-density lipoprotein cholesterol; FSH — follicle stimulating hormone; LH — luteinizing hormone; T. Testosterone — serum total testosterone; 
HOMA-IR — homeostatic model assessment of insulin resistance; hs-CRP — high-sensitivity C-reactive protein; ADMA — asymmetric dimethylarginine;  
TyG Index — triglyceride–glucose index
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It is well-known that patients with hypogonad-
ism are at increased cardiometabolic risk [2, 17, 18]. 
Although the exact mechanism of increased cardio-
vascular risk of patients with hypogonadism is not 
clear, the classical pathways of atherosclerosis such 
as endothelial dysfunction, insulin resistance, and 
inflammation are thought to be involved [3, 19, 20]. 
Nitric oxide (NO), an endothelium derived mediator, is 
a potent endogenous vasodilator, and decreased levels 
of NO may cause endothelial dysfunction and increased 
risk of cardiovascular disease. ADMA, an endogenous 
inhibitor of nitric oxide synthase, is a well-known sur-
rogate marker of endothelial dysfunction [21]. Also, 
the HOMA-IR level is a well-known surrogate marker 
of insulin resistance [22]. In the present study, the 
worse lipid profile, and higher waist circumference 
and insulin levels in patients with CHH indicate that 
these patients had metabolic derangements.  Also, we 
showed again that patients with CHH have increased 
ADMA and HOMA-IR levels when compared with 
healthy subjects. These findings imply that patients 
with CHH have impaired endothelial functions and 
increased insulin resistance even at younger ages [15, 
23]. However, these surrogate markers are generally 
used in scientific studies and are not practical to show 
the increased cardiometabolic risk of patients with 
hypogonadism in daily use.
The TyG index is a novel surrogate marker of in-
sulin resistance, first proposed by Guerrero-Romero 
et al. in 2008 [7]. Previous studies reported that the 
TyG index correlates greatly with hyperinsulinaemic 
euglycaemic clamp test and HOMA-IR levels [7, 8, 10]. 
TyG index levels also increased in many cardiometabolic 
diseases such as coronary artery disease, hypertension, 
type 2 diabetes, obesity, and metabolic syndrome, all 
of which have increased prevalence in patients with 
hypogonadism [11, 14, 24]. In the present study, we 
showed that TyG index levels were higher in patients 
with CHH compared to the healthy subjects. To our 
knowledge, there are no data showing the TyG index 
levels in patients with CHH. However, there is a study 
that indicates the TyG index levels in patients with 
hypogonadism [25]. In this study, Zhang et al. found 
out that patients with hypogonadism had significantly 
higher TyG index levels compared with men without 
hypogonadism. However, the patients with hypogo-
nadism in this study were elderly, and the aetiology 
of hypogonadism is not clear. Similarly, we showed 
higher TyG index levels in younger and treatment-naïve 
patients with CHH. 
HOMA-IR levels have been used in many stud-
ies to detect insulin resistance. However, it is not 
a practical method for measuring insulin resistance on 
an individual basis, and it is used mostly in scientific 
studies. Previous studies reported that the TyG index 
could be used as a surrogate marker for insulin resis-
tance instead of HOMA-IR [8]. In our study, we found 
that the TyG index correlated with both ADMA and 
HOMA-IR levels. Moreover, with waist circumference, 
the TyG index was the independent determinant of the 
HOMA-IR levels. Zhang et al. found out that the TyG in-
dex had better predictive power for hypogonadism than 
HOMA-IR [25]. We found that the TyG index also had 
predictive power for HOMA-IR levels even in younger 
and treatment-naïve patients with CHH. These find-
ings imply that the TyG index may be used as a simple 
and practical measure to predict insulin resistance in 
patients with CHH. Additionally, increased TyG index 
Table 3. Linear regression analysis using asymmetric dimethylarginine (ADMA) and homeostatic model assessment of insulin 
resistance (HOMA-IR) as the dependent variables
Dependent Variable Independent variables B coefficient t value p
ADMA [µmol/L]
BMI [kg/m2] –0.050 –0.451 0.654
HDL [mg/dL] 0.011 0.101 0.920
LDL [mg/dL] 0.118 1.111 0.271
TyG Index 0.104 0.929 0.357
T. Testosterone [ng/mL] –0.707 –3.367 0.001
FSH [mIU/mL] –0.068 –0.334 0.740
LH [mIU/mL] 0.208 0.903 0.370
HOMA-IR
BMI [kg/m2] 0.075 0.623 0.535
WC [cm] 0.259 2.026 0.045
TyG Index 0.197 2.402 0.018
T. Testosterone [ng/mL] 0.133 –1.504 0.135
BMI — body mass index; WC — waist circumference; LDL — low-density lipoprotein cholesterol; HDL — high-density lipoprotein cholesterol; FSH — follicle 
stimulating hormone; LH — luteinizing hormone; T. Testosterone — serum total testosterone; HOMA-IR — homeostatic model assessment of insulin resistance;  
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levels and its correlation with ADMA and HOMA-IR 
levels may mean that this index may be an indicator of 
increased cardiovascular risk in these patients.
There are several limitations and strengths of the 
present study. First of all, the cross-sectional design 
of the study may preclude further mechanistic com-
ments. In addition, the study population, comprising 
young, treatment-naïve patients with CHH, may not 
be representative of the general population of patients 
with hypogonadism. Finally, the small sample size 
may be another limitation; however, treatment-naive 
adults with CHH are uncommon, and we think that 
the number of subjects in this study was adequate for 
evaluation. Despite these limitations, the presence of 
the homogeneous study population and the lack of 
confounding factors, such as chronic metabolic disor-
ders and concomitant medications, are the strengths 
of the study.
Conclusions
The present study shows that patients with CHH have 
increased TyG index levels, which are significantly 
correlated with the surrogate markers of endothelial 
dysfunction and insulin resistance. Moreover, the TyG 
index has an independent predictive power for insulin 
resistance in treatment-naïve young patients with CHH. 
However, prospective long-term studies are warranted 
to find out the role of the TyG index in determining 
cardiometabolic risk in patients with hypogonadism. 
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